A new class of diabetes drugs called the SGLT2 or Sodium GLucose coTransport 2 have been developed. The first to come to market is called Invokana.
These drugs block the reabsorption of glucose in the kidneys, and cause glucose or sugar, to be spilled in the urine. This lowers blood glucose, as well as weight loss. The loss of 40-80 grams of sugar in the urine equates to 160-320 calories per day, or 15-30 minutes of exercise equivalent.
The major side effect is vaginal yeast infections and urinary tract infections from the sugar feeding yeast and bacteria. They may also increase the risk od bladder cancer. In fact another drug in this family, Daptogloflozin, was blocked from being released to market until further cancer studies can be done